A detailed history of Kynam Capital Management, LP transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Kynam Capital Management, LP holds 4,899,497 shares of WVE stock, worth $65.7 Million. This represents 3.3% of its overall portfolio holdings.

Number of Shares
4,899,497
Previous 3,975,521 23.24%
Holding current value
$65.7 Million
Previous $19.8 Million 102.53%
% of portfolio
3.3%
Previous 1.54%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.12 - $9.01 $4.73 Million - $8.33 Million
923,976 Added 23.24%
4,899,497 $40.2 Million
Q2 2024

Aug 14, 2024

BUY
$4.38 - $6.48 $190,262 - $281,484
43,439 Added 1.1%
3,975,521 $19.8 Million
Q3 2023

Nov 14, 2023

BUY
$3.56 - $5.75 $26,628 - $43,010
7,480 Added 0.19%
3,932,082 $22.6 Million
Q2 2023

Aug 14, 2023

BUY
$3.51 - $4.69 $409,708 - $547,444
116,726 Added 3.07%
3,924,602 $14.3 Million
Q1 2023

May 15, 2023

BUY
$3.58 - $6.3 $9.2 Million - $16.2 Million
2,569,694 Added 207.54%
3,807,876 $16.5 Million
Q4 2022

Feb 14, 2023

SELL
$3.18 - $7.0 $506,564 - $1.12 Million
-159,297 Reduced 11.4%
1,238,182 $8.67 Million
Q3 2022

Nov 14, 2022

SELL
$2.37 - $4.28 $709,236 - $1.28 Million
-299,256 Reduced 17.64%
1,397,479 $5.05 Million
Q2 2022

Aug 15, 2022

SELL
$1.23 - $3.25 $264,441 - $698,727
-214,993 Reduced 11.25%
1,696,735 $5.51 Million
Q1 2022

May 13, 2022

BUY
$2.0 - $3.28 $834,268 - $1.37 Million
417,134 Added 27.91%
1,911,728 $3.82 Million
Q4 2021

Feb 14, 2022

BUY
$3.14 - $5.15 $4.69 Million - $7.7 Million
1,494,594 New
1,494,594 $4.69 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.16B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.